Search research articles
Contact Us
Filters
Showing results (111-120 of 127) with videos related to
Page
of 13
Sort By:
Leukemia
|
January 6, 2024
Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma
Luise Fischer, Nora Grieb, Patrick Born, et al.
Journal of Hematology & Oncology
|
May 21, 2026
Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry analysis
Nico Gagelmann, Hermann Einsele, Sarah Flossdorf, et al.
Hemasphere
|
January 17, 2025
Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study
Maximilian Merz, Anca-Maria Albici, Bastian von Tresckow, et al.
BMC Cancer
|
April 27, 2016
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma
Marc-Andrea Baertsch, Jana Schlenzka, Elias K Mai, et al.
Leukemia
|
February 17, 2026
MyCARdiac score: integrating cardiac imaging and biomarkers to predict outcomes in RRMM patients receiving cilta-cel
Thomas C Wiemers, Nora Grieb, Maximilian Ferle, et al.
Leukemia
|
February 9, 2020
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial
Hartmut Goldschmidt, Elias K Mai, Jan Dürig, et al.
Medrxiv : the Preprint Server for Health Sciences
|
November 24, 2025
Robust CD4<sup>+</sup> CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene Autoleucel
Eric M Jurgens, Sneha Mitra, Kevin Herrera, et al.
Nature Cancer
|
April 19, 2024
Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma
Michael Rade, Nora Grieb, Ronald Weiss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2024
Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
Nico Gagelmann, Danai Dima, Maximilian Merz, et al.
Hemasphere
|
April 18, 2025
A German multicenter real-world analysis of talquetamab in 138 patients with relapsed/refractory multiple myeloma
Jan H Frenking, Christine Riedhammer, Raphael Teipel, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 127) with videos related to
Sort By:
Page
of 13
Leukemia
|
January 6, 2024
Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma
Luise Fischer, Nora Grieb, Patrick Born, et al.
Journal of Hematology & Oncology
|
May 21, 2026
Standard-of-care ciltacabtagene autoleucel in earlier versus later lines of therapy for relapsed or refractory multiple myeloma: a nationwide registry analysis
Nico Gagelmann, Hermann Einsele, Sarah Flossdorf, et al.
Hemasphere
|
January 17, 2025
Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study
Maximilian Merz, Anca-Maria Albici, Bastian von Tresckow, et al.
BMC Cancer
|
April 27, 2016
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma
Marc-Andrea Baertsch, Jana Schlenzka, Elias K Mai, et al.
Leukemia
|
February 17, 2026
MyCARdiac score: integrating cardiac imaging and biomarkers to predict outcomes in RRMM patients receiving cilta-cel
Thomas C Wiemers, Nora Grieb, Maximilian Ferle, et al.
Leukemia
|
February 9, 2020
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial
Hartmut Goldschmidt, Elias K Mai, Jan Dürig, et al.
Medrxiv : the Preprint Server for Health Sciences
|
November 24, 2025
Robust CD4<sup>+</sup> CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene Autoleucel
Eric M Jurgens, Sneha Mitra, Kevin Herrera, et al.
Nature Cancer
|
April 19, 2024
Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma
Michael Rade, Nora Grieb, Ronald Weiss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2024
Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
Nico Gagelmann, Danai Dima, Maximilian Merz, et al.
Hemasphere
|
April 18, 2025
A German multicenter real-world analysis of talquetamab in 138 patients with relapsed/refractory multiple myeloma
Jan H Frenking, Christine Riedhammer, Raphael Teipel, et al.
Page
of 13